Day Two
Program
Day 2: Tuesday, October 23, 2018
Session C – Cancer Immunology
Studying interactions between the immune system and cancer cells is a growing field of research that aims to discover innovative cancer immunotherapies to treat and stunt the progression of the disease. Immuno-oncology research and development of immunotherapies continues to advance the fight against cancer. Using methods such as combination targeted therapies and immune modulators offers a broader understanding on a wider range of cancers.
Chairpersons and Discussants:
Jeff Schlom, PhD, National Cancer Institute, US
Eduardo Sotomayor, MD PhD, George Washington University, US
Schedule:
9:00 AM
Opening Remarks
Yang Liu, PhD, Institute of Human Virology, University of Maryland School of Medicine, US
9:00 AM
Presentation Title: Sialoside-based pattern recognition and its application in immunotherapy
Speaker: Yang Liu, PhD, Institute of Human Virology, University of Maryland School of Medicine, US
9:30 AM
Presentation Title: Early Stage Non Small Cell Lung Cancer
Speaker: Julie Brahmer, MD, Johns Hopkins University, US
9:55 AM
Presentation Title: Multimodal Approach to Cancer Immunotherapy
Speaker: Jeffrey Schlom, PhD, National Cancer Institute, US
Coffee Break, 10:20 AM - 10:40 AM
10:40 AM
Presentation Title: Development of cancer immunotherapy by targeting neoantigens
Speaker: Rongfu Wang, PhD, Weill Cornell Medical College, US
11:05 AM
Presentation Title: Clinical trial of HER2 cancer vaccine shows benefit in 45% of evaluable patients in phase I study
Speaker: Jay Berzofsky, MD, PhD, National Cancer Institute, US
11:30 AM
Presentation Title: Tumor targeting antibodies to improve tumor immunity: the role of microbiota
Speaker: Yang-Xin Fu, MD, PhD, UT Southwestern Medical Center, US
11:55 AM
Presentation Title: How Checkpoint Blockade alters the repertoire and function of tumor specific T-cells
Speaker: Drew Pardoll, MD PhD, Bloomberg-Kimmel Institute for Cancer Immunotherapy, US
Lunch Break, 12:20 PM - 1:25 PM
Session D – Cancer Epigenetics
Epigenetics, a rapidly expanding field focusing on changes in gene expression in the absence of DNA sequence changes, is now known to be a fundamental mechanism in cancer. Disruption of the epigenome plays a causative role in cancer biology. Understanding that epigenetic alterations are critical genetic mutations in cellular transformation to cancer holds great promise for cancer prevention, detection, and therapy.
Chairpersons and Discussants:
Mark Kaplan, MD, University of Michigan, US
Clement Adebamowo, MD, Institute of Human Virology, University of Maryland School of Medicine, US
Schedule:
1:25 PM
Presentation Title: Expression of evolutionary novel genes in tumors - the possible role of tumors in evolution
Speaker: Andrei Kozlov, PhD, The Biomedical Center, Russia
1:50 PM
Presentation Title: TBD
Speaker: TBD
2:15 PM
Presentation Title: From the laboratory into the clinic: cancer terminator viruses and genetic-based imaging of metastasis
Speaker: Paul Fisher, MPh PhD, FNAI, Virginia Commonwealth University, US
2:40 PM
Presentation Title: Harnessing Reprogramming of the Tumor Microenvironment with Entinostat to Augment Tumor Sensitivity to Multivalent Immunotherapy Combinations with an IL-15 Superagonist plus Vaccine or Immune Checkpoint Blockade
Speaker: Sofia Gameiro, Pharm.D, PhD, National Cancer Institute, US
3:05 PM
Presentation Title: Cellular memory and rare cell variability in cancer
Speaker: Sydney Shaffer, MD PhD, University of Pennsylvania, US
Coffee Break, 3:30 PM - 3:55 PM
Session E – Cancer Microenvironments
The tumor microenvironment (TME) includes blood vessels, immune cells, fibroblasts, bone marrow derived inflammatory cells, lymphocytes, signaling molecules and the extracellular matrix. The TME plays an integral role in creating restraint or further progression of the proliferation, survival, and migration of tumor cells.
Chairpersons and Discussants:
Isaac Witz, PhD, Tel Aviv University, Israel
Franco Buonaguro, MD, Istituto Nazionale Tumori Fondazione Pascale, Italy
Schedule:
3:55 PM
Opening Remarks
Isaac Witz, PhD, Tel Aviv University, Israel
4:05 PM
Presentation Title: UPR in coordinated regulation of microbiome and anti-tumor immunity
Speaker: Ze'ev Ronai, PhD, Technion Israel Institute of Technology, Israel
4:30 PM
Presentation Title: Destruction of the tumor microenvironment by neoantigen-specific T cells prevents relapse of therapy-resistant cancer variants
Speaker: Hans Schreiber, MD, PhD, University of Chicago, US
4:55 PM
Presentation Title: Inflammation-driven networks in the regulation of breast cancer progression
Speaker: Adit Ben-Baruch, PhD, Tel Aviv University, Israel
5:20 PM
Presentation Title: Intravital microscopy of the tumor microenvironment: escape and relevance for immunotherapy
Speaker: Peter Friedl, MD, PhD, Radboud University, Netherlands
5:45 PM
Presentation Title: Mesenchymal Stromal Cells: Mediators of Inflammation in Cancer
Speaker: Yves Declerck, MD, Univeristy of Southern California, US
Poster Session, 6:15 PM - 8:15 PM